Esophageal Carcinoma Clinical Trials

22 recruiting

Esophageal Carcinoma Trials at a Glance

32 actively recruiting trials for esophageal carcinoma are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in New York, Oklahoma City, and Houston. Lead sponsors running esophageal carcinoma studies include M.D. Anderson Cancer Center, Fudan University, and Mayo Clinic.

Browse esophageal carcinoma trials by phase

Treatments under study

About Esophageal Carcinoma Clinical Trials

Looking for clinical trials for Esophageal Carcinoma? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Esophageal Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Esophageal Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 32 trials

Recruiting
Not Applicable

The Vanguard Study: Testing a New Way to Screen for Cancer

Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled37 locationsNCT06995898
Recruiting
Phase 3

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Esophageal CancerOesophageal CancerSquamous Cell Esophageal Carcinoma
Sun Yat-sen University422 enrolled1 locationNCT05357846
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 3

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Esophageal CarcinomaRadiotherapyImmunotherapy
Fudan University452 enrolled1 locationNCT06964568
Recruiting
Not Applicable

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

Esophageal CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+14 more
M.D. Anderson Cancer Center400 enrolled1 locationNCT03948100
Recruiting
Phase 2

Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy

Advanced or Metastatic Gastrooesophageal Carcinoma
National Cancer Institute, Naples84 enrolled1 locationNCT07213557
Recruiting
Phase 1

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Urothelial CarcinomaDiffuse Pleural MesotheliomaGastroesophageal Carcinoma
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07532902
Recruiting
Not Applicable

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Esophageal CarcinomaGastric CarcinomaGastroesophageal Junction Carcinoma+7 more
Alliance for Clinical Trials in Oncology420 enrolled287 locationsNCT07283939
Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Metastatic Cervical CarcinomaMetastatic Endometrial CarcinomaMetastatic Lung Non-Small Cell Carcinoma+24 more
Mayo Clinic324 enrolled3 locationsNCT06349642
Recruiting

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

Esophageal Carcinoma
M.D. Anderson Cancer Center60 enrolled1 locationNCT06549413
Recruiting
Not Applicable

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

Esophageal CarcinomaLung Carcinoma
Thomas Jefferson University20 enrolled1 locationNCT05775939
Recruiting
Phase 2

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Locally Advanced Hepatocellular CarcinomaLocally Advanced Gastric CarcinomaAdvanced Biliary Tract Carcinoma+7 more
OHSU Knight Cancer Institute66 enrolled1 locationNCT05705492
Recruiting
Not Applicable

Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)

Esophageal CancerEsophageal Carcinoma
University of Pittsburgh20 enrolled1 locationNCT06872515
Recruiting
Phase 3

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

Esophageal CarcinomaRadiotherapyImmunotherapy
Fudan University432 enrolled1 locationNCT06676449
Recruiting

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Breast CarcinomaEsophageal CarcinomaHead and Neck Carcinoma+6 more
M.D. Anderson Cancer Center5,000 enrolled1 locationNCT00991094
Recruiting
Early Phase 1

PET-imaging of Two Vartumabs in Patients With Solid Tumors

Breast CancerBladder CarcinomaEsophageal Carcinoma+11 more
Var2 Pharmaceuticals32 enrolled1 locationNCT06645808
Recruiting
Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Gastric Adenocarcinoma+10 more
Memorial Sloan Kettering Cancer Center37 enrolled7 locationsNCT06251973
Recruiting
Not Applicable

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

Metastatic Gastroesophageal Junction AdenocarcinomaMetastatic Hepatocellular CarcinomaStage IV Hepatocellular Carcinoma AJCC v8+41 more
University of California, San Francisco28 enrolled2 locationsNCT04221893